



KMCH INSTITUTE OF HEALTH SCIENCES AND RESEARCH

(A unit of Kovai Medical Center and Hospital Limited)

99A, Avanashi Road, Coimbatore-641014, Tamilnadu, INDIA

DEPARTMENT OF PHARMACOLOGY

New Drug Update

SERIES – 32

MARCH – 2022



**Drug
Update**

Compiled & Edited by

**Department of
Pharmacology
KMCHIHSR
Coimbatore - 641014**

INSIDE THE SERIES

1. Baclofen
2. Sutimlimab-jome
3. Mitapivat
4. Technetium Tc 99m succimer
5. Amlodipine besylate
6. Filgrastim-ayow
7. Pacritinib

We're on the Web!

www.kmchihsr.edu.in

Mail us:

hodpharmacology@kmchihsr.edu.in

1. Baclofen

Approval date: February 04, 2022

Mechanism of action: Binding to GABA B receptors, causes an influx of potassium into the neuron, leading to hyperpolarization of the neuronal membrane and decreased calcium influx at presynaptic nerve terminals

Indication: Spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity

Dosage formulation: Oral Suspension

2. Sutimlimab – jome

Approval date: February 04, 2022

Mechanism of action: Inhibits the activation of the complement cascade in the immune system and inhibits C1- activated hemolysis in CAD

Indication: Cold Agglutinin Disease (CAD)

Dosage formulation: Injection – IV

3. Mitapivat

Approval date: February 17, 2022

Mechanism of action: Acts by allosterically binding to the pyruvate kinase tetramer and increasing pyruvate kinase (PK) activity

Indication: Pyruvate Kinase Deficiency

Dosage formulation: Tablet

4. Technetium Tc 99m succimer

Approval date: February 22, 2022

Mechanism of action: Radioactive diagnostic agent

Indication: Aid in the scintigraphic evaluation of renal parenchymal disorders

Dosage formulation: Injection Kit (Intravenous)

5. Amlodipine besylate

Approval date: February 24, 2022

Mechanism of action: Calcium channel blocker

Indication: Hypertension and angina in patients with coronary artery disease

Dosage formulation: Oral Solution

6. Filgrastim-ayow

Approval date: February 25, 2022

Mechanism of action: Recombinant human granulocyte colony-stimulating factor biosimilar to Neupogen

Indication: Neutropenia associated with chemotherapy and related conditions

Dosage formulation: Injection (Intravenous or Subcutaneous)

7. Pacritinib

Approval date: February 28, 2022

Mechanism of action: JAK2/FLT3 multikinase inhibitor

Indication: Myelofibrosis patients with severe thrombocytopenia

Dosage formulation: Capsules